Supplementary Figure 1.tif (29.66 MB)
Download file

Supplementary Figure 1: Impact of ALK fusion variant on clinical outcomes in EML4-ALK NSCLC patients: a systematic review and meta-analysis

Download (29.66 MB)
figure
posted on 16.11.2021, 15:55 authored by Shasha Wang, Rongrong Luo, Yuankai Shi, Xiaohong Han
Supplementary Figure 1: Impact of ALK Fusion Variant on Clinical Outcomes in EML4-ALK NSCLC Patients: a systematic review and meta-analysis.
Sensitivity analyses for overall PFS and OS in ALK-positive NSCLC patients. (A) Overall PFS in v1 vs non-v1; (B) Overall OS in v1 vs non-v1; (C) Overall PFS in v3 vs non-v3; (D) Overall OS in v3 vs non-v3; (E) Overall PFS in short-form variant vs long-form variant; (F) Overall OS in short-form variant vs long-form variant.

Abstract
Background: Emerging studies showed that ALK-fusion variants were associated with heterogeneous clinical outcomes. However, contradicting conclusions drew in some other studies considered no correlation between ALK variants and prognoses. Methods: we performed a systematic review and meta-analysis to evaluated the prognostic value of EML4-ALK fusion variants for the outcome of patients. Results: 28 studies were included in our analysis. According to the pooled results, patients harboring variant 1 showed equivalent PFS and OS with non-v1 (HR for PFS: 0.91(0.68-1.21), p=0.499; for OS: 1.12(0.73-1.72), p=0.610). Similarly, patients with v3 showed the same disease progress with non-v3 (pooled HR for PFS=1.07(0.72-1.58), p=0.741). However, pooled results for OS suggested that patients with v3 had a worse survival than non-v3 (HR=3.44(1.42-8.35), p=0.006). Conclusion: Overall results suggested that patients with v1 exhibited no significant difference with non-v1 in terms of OS and PFS, while v3 was associated with shorter OS in ALK-positive NSCLC patients.


Funding

This work was supported by the grant from the National Natural Science Foundation of China (No.81871739) and China National Major Project for New Drug Innovation (No.2019ZX09201002, No.2017ZX09304015)

History